文献速递头颈部肿瘤放疗放疗物理与技术

口咽癌质子治疗的个体化生活质量获益与成本效果估计

Individualized quality of life benefit and cost-effectiveness estimates of proton therapy for patients with oropharyngeal cancer.
PubMed 文献 · Radiat Oncol · 2021-01-21

本研究基于33例接受根治性放疗的口咽癌患者,用正常组织并发症概率模型比较IMRT与IMPT计划,估算吞咽困难、食管炎、甲状腺功能减退、口干和口腔黏膜炎的风险及QALY损失,并结合成本建模与蒙特卡罗敏感性分析。结果显示ICER在患者间差异很大,中位361405美元/QALY,p16阳性者更可能具有成本效果。

要点

  • 质子治疗的成本效果在口咽癌患者间差异很大,支持个体化决策。
  • 全组ICER中位361405美元/QALY,个体间从54477到1508845美元/QALY。
  • p16阳性者ICER为234201美元/QALY,低于p16阴性者的516297美元/QALY。

核心结论

  • 质子治疗在口咽癌患者中的成本效果差异很大,识别最可能获益的患者有助于优化资源配置并指导前瞻性临床试验设计。

研究设计与样本

  • 对33例接受根治性放疗的口咽癌患者,用正常组织并发症概率模型比较已交付的光子IMRT计划与IMPT计划。
  • 计算每种并发症的QALY损失,并纳入患者特异性条件生存概率和基于并发症严重程度的质量调整因子。
  • 基于IMPT与IMRT的前期成本及急性和/或长期并发症管理成本进行成本效果建模,并通过蒙特卡罗抽样纳入参数不确定性和敏感性分析。

主要发现

  • ICER显示患者间每获得一个QALY的成本差异很大,全组中位361405美元/QALY,个体间从54477到1508845美元/QALY。
  • p16阳性肿瘤患者的ICER为234201美元/QALY,p16阴性肿瘤患者为516297美元/QALY。
  • p16阳性且接受全面淋巴结照射的患者中,在500000美元/QALY阈值下,8/9例被估计在≥50%抽样中具有成本效果。
  • p16阴性或接受单侧颈部照射的患者中,在500000美元/QALY阈值下,6/24例被估计在≥50%抽样中具有成本效果。

关键数值与推荐

  • 全组ICER中位361405美元/QALY,个体间范围54477至1508845美元/QALY。
  • p16阳性肿瘤ICER为234201美元/QALY,p16阴性肿瘤ICER为516297美元/QALY。
  • 在500000美元/QALY阈值下,p16阳性且全面淋巴结照射者8/9例在≥50%抽样中具有成本效果。
  • 在500000美元/QALY阈值下,p16阴性或单侧颈部照射者6/24例在≥50%抽样中具有成本效果。

临床怎么用

  • 可将个体化成本效果估计作为口咽癌质子治疗决策的辅助工具,优先考虑最可能获益的患者。
  • p16阳性且接受全面淋巴结照射的患者在较高支付意愿阈值下更可能具有成本效果。
  • 前期成本、社会支付意愿和医疗管理在不同国家差异很大,应用时需结合本地情况。

局限性

  • 样本量为33例,来源于单组计划比较与模型估算。
  • 成本效果结论受模型参数不确定性和蒙特卡罗抽样影响。
  • 前期成本、社会支付意愿和医疗管理在不同国家差异很大。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Proton therapy is a promising advancement in radiation oncology especially in terms of reducing normal tissue toxicity, although it is currently expensive and of limited availability. Here we estimated the individual quality of life benefit and cost-effectiveness of proton therapy in patients with oropharyngeal cancer treated with definitive radiation therapy (RT), as a decision-making tool for treatment individualization. METHODS AND MATERIALS: Normal tissue complication probability models were used to estimate the risk of dysphagia, esophagitis, hypothyroidism, xerostomia and oral mucositis for 33 patients, comparing delivered photon intensity-modulated RT (IMRT) plans to intensity-modulated proton therapy (IMPT) plans. Quality-adjusted life years (QALYs) lost were calculated for each complication while accounting for patient-specific conditional survival probability and assigning quality-adjustment factors based on complication severity. Cost-effectiveness was modeled based on upfront costs of IMPT and IMRT, and the cost of acute and/or long-term management of treatment complications. Uncertainties in all model parameters and sensitivity analyses were included through Monte Carlo sampling. RESULTS: The incremental cost-effectiveness ratios (ICERs) showed considerable variability in the cost of QALYs spared between patients, with median $361,405/QALY for all patients, varying from $54,477/QALY to $1,508,845/QALY between individual patients. Proton therapy was more likely to be cost-effective for patients with p16-positive tumors ($234,201/QALY), compared to p16-negative tumors ($516,297/QALY). For patients with p16-positive tumors treated with comprehensive nodal irradiation, proton therapy is estimated to be cost-effective in ≥ 50% of sampled cases for 8/9 patients at $500,000/QALY, compared to 6/24 patients who either have p16-negative tumors or receive unilateral neck irradiation. CONCLUSIONS: Proton therapy cost-effectiveness varies greatly among oropharyngeal cancer patients, and highlights the importance of individualized decision-making. Although the upfront cost, societal willingness to pay and healthcare administration can vary greatly among different countries, identifying patients for whom proton therapy will have the greatest benefit can optimize resource allocation and inform prospective clinical trial design.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Brodin NP, Kabarriti R, Schechter CB, et al. Individualized quality of life benefit and cost-effectiveness estimates of proton therapy for patients with oropharyngeal cancer. Radiat Oncol. 2021. PMID: 33478544. doi:10.1186/s13014-021-01745-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。